SWA
CLSD

Stratos Wealth Advisors’s Clearside Biomedical CLSD Stock Holding History

Stratos Wealth Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-933
Closed -$11.2K – 684
2025
Q2 		$11.2K Hold
933
– – ﹤0.01% 668
2025
Q1 		$12.9K Hold
933
– – ﹤0.01% 663
2024
Q4 		$13.3K Hold
933
– – ﹤0.01% 711
2024
Q3 		$17.8K Hold
933
– – ﹤0.01% 732
2024
Q2 		$18.2K Hold
933
– – ﹤0.01% 699
2024
Q1 		$21.4K Hold
933
– – ﹤0.01% 658
2023
Q4 		$16.4K Hold
933
– – ﹤0.01% 680
2023
Q3 		$12.2K Buy
+933
New +$14.1K ﹤0.01% 663

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stratos Wealth Advisors's CLSD Position: Q3 2025 in Review

Stratos Wealth Advisors sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 933 shares — an estimated $11.2K sold.

Stratos Wealth Advisors first reported a position in CLSD in Q3 2023 and held it in 8 quarters. The position peaked at $21.4K in Q1 2024. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • Stratos Wealth Advisors reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • Stratos Wealth Advisors sold 933 Clearside Biomedical shares in Q3 2025, an estimated $11.2K.
  • Stratos Wealth Advisors first reported a position in Clearside Biomedical in Q3 2023 and held it in 8 quarters.
  • Stratos Wealth Advisors's Clearside Biomedical position peaked at $21.4K in Q1 2024.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Stratos Wealth Advisors's 13F filing for Q3 2025, filed 6 Nov 2025.